http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
전송선 감소를 위한 듀얼레벨 저전압 차동신호 전송(DLVDS) 기법
김두한,양성현,조경록,Kim Doo-Hwan,Yang Sung-Hyun,Cho Kyoung-Rok 대한전자공학회 2005 電子工學會論文誌-SD (Semiconductor and devices) Vol.42 No.8
본 논문은 LCD driver IC의 전송선 수를 줄이기 위한 이중 저전압 차동신호 전송(DLVDS) 회로를 제안한다. 제안된 회로에서는 2-비트 원시 데이터를 하나의 송신기에서 입력 받고, 2-비트 데이터를 듀얼레벨을 갖는 차동신호로 전송한다. 따라서 기존의 저전압 차동신호 전송기법(LVDS)의 특징을 유지하면서 2-비트 원시 데이터를 2개의 전송선을 통하여 전송할 수 있다. 수신기에서는 디코드 회로를 통해 원래의 2-비트 원시 입력 데이터를 복원할 수 있다. 제안된 회로는 $0.25\mu m$ CMOS 공정으로 설계하여, 1-Gbps/2-line의 전송률을 갖고, 2.5V의 전원에서 35-mW의 전력소모를 나타냈다. A dual-level low voltage differential signalling (DLVDS) circuit is proposed aiming at reducing transmission lines for LCD driver IC. In the proposed circuit, we apply a couple of primitive data to DLVDS circuit as inputs. The transmitter converts two inputs to two kinds of fully differential level signals. In this circuit, two transmission lines are sufficient to transfer two primitive inputs while keeping the LVDS feature. The receiver recovers The original input data through a level decoding circuit. We fabricated the proposed circuit using $0.25\mu m$ CMOS technology. The resultant circuit shows 1-Gbps/2-line data rate and 35-mW power consumption at 2.5V supply voltage, respectively.
이경렬 ( Kyung Real Lee ),김두한 ( Doo Hwan Kim ),윤문수 ( Moon Soo Yoon ) 대한피부과학회 2007 大韓皮膚科學會誌 Vol.45 No.4
Background: Bowen`s disease is a challenging condition to treat because lesions often affect the elderly who are usually intolerable to invasive treatment modalities and lesions are often located at sites that heal poorly. Objective: The aim of this study was to evaluate the effectiveness and the safety of 5% imiquimod cream for the treatment of Bowen`s disease. Methods: Eleven patients with biopsy-proven Bowen`s disease were treated with once-daily or twice-daily self-application of 5% imiquimod cream for a maximum of 16 weeks. Results: Nine of ten (90%) patients who completed the treatment schedule showed complete clinicopathologic regression. One (11%) patient showed recurrence of Bowen`s disease on the treated site. 5% imiquimod cream was generally well-tolerated and no serious side effects were observed. Conclusion: 5% imiquimod cream appears to be an effective modality for treatment of Bowen`s disease and might represent a valuable alternative to surgery or other invasive treatment methods. (Korean J Dermatol 2007;45(4):338~344)
화농성 육아종에 대한 5% Imiquimod 크림의 치료 효과
김세희 ( Se Hee Kim ),윤문수 ( Moon Soo Yoon ),김두한 ( Doo Hwan Kim ) 대한피부과학회 2006 대한피부과학회지 Vol.44 No.9
Background: Conventional interventions for pyogenic granuloma include excision, electrodessication and curettage, cryotherapy, and laser ablation, all of which can be associated with local tissue destruction, scarring, and recurrence in some cases. Although imiquimod is commonly regarded as an immune response modifier, it also induces antiangiogenic factors such as tissue inhibition of matrix metalloproteinase-1 (TIMP-1), IL-12 and increases apoptosis in vascular tumors. Objective: To investigate the therapeutic efficacy of imiquimod on pyogenic granuloma. Methods: Twelve patients with pyogenic granuloma were treated with 5% imiquimod cream every night for up to 8 weeks. Therapeutic efficacy, side effects and patient`s satisfaction scale were evaluated. Results: The onset time of effects ranged from 1 to 11 days (mean: 4.6 days). The clearance rate at 8 weeks after treatment was 83.3% and the mean time for clearance was 3.6 weeks. 3 of 12 (25%) patients experienced local pain, erosion and hemorraging as adverse events. However, there has been no recurrence, scarring, or hypopig-mentation after more than 8 months of follow-up. Conclusion: Imiquimod may represent a safe, simple and effective alternative in the management of pyogenic granuloma. This therapeutic modality may be of particular benefit in children and patients whose lesions are on the face. (Korean J Dermatol 2006;44(9):1078~1083)